INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION

INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION

PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formul...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TOMIYOSHI TSUGIO, SHIOZAWA AKIRA, HOSHINO KOUROU, IKEDA RYUJI
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator TOMIYOSHI TSUGIO
SHIOZAWA AKIRA
HOSHINO KOUROU
IKEDA RYUJI
description PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formula I [Gu is guanidino; X0 is (CH2)1-5, (substituted)phenylene; (a) is 3-5; X1 (CH2)0-2-CH(CH00)(CH2)0-2 (R00 is H, OH, OCH3, etc); X2 is NH(CH2)4 NH (CH2)3NH-R02 (R02 is H, the OH-removed residue of the carboxyl group of an amino acid or peptide)] or a spergualin-related compound (salt) of formula II [X is (CH2)1-5, C6H4; (r) is 3-5; R6 is the residue produced by removing one H atom from the alpha-amino group and a hydroxyl group from the alpha-carboxyl group of an amino acid, etc.]. The compound is orally administered at a dose of preferably 5-500mg/kg.day.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH06192075A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH06192075A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH06192075A3</originalsourceid><addsrcrecordid>eNqNyjEKwjAUANAsDqLe4XuAQlVUHNPkx3whPzZNhEylSJxEC_X-uHgAp7e8uXDElhqKPmSQZ-QIxgewyUkGqdpEATWQc4m9RkOKkFWGLrMO3iHcKKQOiA2qSJ6XYvYYnlNZ_VyItcGobFXGd1-mcbiXV_n0l6utD5vTtj7u5e6f8wUfhi7h</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION</title><source>esp@cenet</source><creator>TOMIYOSHI TSUGIO ; SHIOZAWA AKIRA ; HOSHINO KOUROU ; IKEDA RYUJI</creator><creatorcontrib>TOMIYOSHI TSUGIO ; SHIOZAWA AKIRA ; HOSHINO KOUROU ; IKEDA RYUJI</creatorcontrib><description>PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formula I [Gu is guanidino; X0 is (CH2)1-5, (substituted)phenylene; (a) is 3-5; X1 (CH2)0-2-CH(CH00)(CH2)0-2 (R00 is H, OH, OCH3, etc); X2 is NH(CH2)4 NH (CH2)3NH-R02 (R02 is H, the OH-removed residue of the carboxyl group of an amino acid or peptide)] or a spergualin-related compound (salt) of formula II [X is (CH2)1-5, C6H4; (r) is 3-5; R6 is the residue produced by removing one H atom from the alpha-amino group and a hydroxyl group from the alpha-carboxyl group of an amino acid, etc.]. The compound is orally administered at a dose of preferably 5-500mg/kg.day.</description><edition>5</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1994</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19940712&amp;DB=EPODOC&amp;CC=JP&amp;NR=H06192075A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19940712&amp;DB=EPODOC&amp;CC=JP&amp;NR=H06192075A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TOMIYOSHI TSUGIO</creatorcontrib><creatorcontrib>SHIOZAWA AKIRA</creatorcontrib><creatorcontrib>HOSHINO KOUROU</creatorcontrib><creatorcontrib>IKEDA RYUJI</creatorcontrib><title>INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION</title><description>PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formula I [Gu is guanidino; X0 is (CH2)1-5, (substituted)phenylene; (a) is 3-5; X1 (CH2)0-2-CH(CH00)(CH2)0-2 (R00 is H, OH, OCH3, etc); X2 is NH(CH2)4 NH (CH2)3NH-R02 (R02 is H, the OH-removed residue of the carboxyl group of an amino acid or peptide)] or a spergualin-related compound (salt) of formula II [X is (CH2)1-5, C6H4; (r) is 3-5; R6 is the residue produced by removing one H atom from the alpha-amino group and a hydroxyl group from the alpha-carboxyl group of an amino acid, etc.]. The compound is orally administered at a dose of preferably 5-500mg/kg.day.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1994</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyjEKwjAUANAsDqLe4XuAQlVUHNPkx3whPzZNhEylSJxEC_X-uHgAp7e8uXDElhqKPmSQZ-QIxgewyUkGqdpEATWQc4m9RkOKkFWGLrMO3iHcKKQOiA2qSJ6XYvYYnlNZ_VyItcGobFXGd1-mcbiXV_n0l6utD5vTtj7u5e6f8wUfhi7h</recordid><startdate>19940712</startdate><enddate>19940712</enddate><creator>TOMIYOSHI TSUGIO</creator><creator>SHIOZAWA AKIRA</creator><creator>HOSHINO KOUROU</creator><creator>IKEDA RYUJI</creator><scope>EVB</scope></search><sort><creationdate>19940712</creationdate><title>INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION</title><author>TOMIYOSHI TSUGIO ; SHIOZAWA AKIRA ; HOSHINO KOUROU ; IKEDA RYUJI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH06192075A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1994</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TOMIYOSHI TSUGIO</creatorcontrib><creatorcontrib>SHIOZAWA AKIRA</creatorcontrib><creatorcontrib>HOSHINO KOUROU</creatorcontrib><creatorcontrib>IKEDA RYUJI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TOMIYOSHI TSUGIO</au><au>SHIOZAWA AKIRA</au><au>HOSHINO KOUROU</au><au>IKEDA RYUJI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION</title><date>1994-07-12</date><risdate>1994</risdate><abstract>PURPOSE:To provide the subject inhibitor containing a specific spergualin-related compound as an active ingredient, low in toxicity, and excellent in safety, antitumor activity and immune-enhancing activity. CONSTITUTION:The objective inhibitor contains a spergualin-related compound (salt) of formula I [Gu is guanidino; X0 is (CH2)1-5, (substituted)phenylene; (a) is 3-5; X1 (CH2)0-2-CH(CH00)(CH2)0-2 (R00 is H, OH, OCH3, etc); X2 is NH(CH2)4 NH (CH2)3NH-R02 (R02 is H, the OH-removed residue of the carboxyl group of an amino acid or peptide)] or a spergualin-related compound (salt) of formula II [X is (CH2)1-5, C6H4; (r) is 3-5; R6 is the residue produced by removing one H atom from the alpha-amino group and a hydroxyl group from the alpha-carboxyl group of an amino acid, etc.]. The compound is orally administered at a dose of preferably 5-500mg/kg.day.</abstract><edition>5</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_JPH06192075A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title INHIBITORY AGENT FOR HUMAN ACQUIRED IMMUNODEFICIENCY SYNDROME VIRUS INFECTION
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T19%3A21%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TOMIYOSHI%20TSUGIO&rft.date=1994-07-12&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH06192075A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true